Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

In DETECT AS, the passive notifications improved rates of AVR and boosted survival, with bigger gains in women.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

In an early look at SCOT-HEART 2, CCTA led more primary-prevention patients to make changes to reduce their risk of CVD.

Acute MI mortality has fallen, yet deaths from other diseases, including heart failure and hypertension, are on the rise.

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Only a minority consistently meet timely targets set out by the AHA and ACC. This is a “call to action,” Harold Dauerman says ...

The observational data can’t capture details like the timing, amount, and type of exposure. Still, there’s a “safety signal.” ...

Elevations in cardiac troponin (cTn) after long bouts of aerobic exercise are not associated with subclinical coronary artery ...

Outcomes in the observational study were better among patients treated by surgeons who regularly do ablations.

The TCTMD news team share their h, from troponin spikes in exercise to GLP-1s in PAD, STEMI delays, and the legacy of ...

The test of nonaerobic functioning may raise awareness that people need to work on balance and flexibility as they age.